Tamarly Lists · Thursday · Life sciences investment

7 trends in life sciences investment this week

From 12 November 2026 to 18 November 2026, 28 biotech and health care companies reported $141.9 million of new private money in SEC Form D filings (company count up 44% on the 4-week average of 19.5), and companies registered 71 new trials, 22 of them at Phase 3.

As of . Research from public records, not investment advice.

  1. Venture money into biotech and health care: 28 operating companies reported Form D sales, $141.9 million in total. Companies up 44% on the 4-week average of 19.5; money down 24% on the 4-week average of $186.4 million.
    Source: SEC Form D
  2. Largest biotech or health care raise: Pelthos Therapeutics Inc. sold $57.5 million. Pharmaceuticals, Form D filed 16 November 2026.
    Source: SEC Form D
  3. New company-sponsored trials: 71 registered. Up 23% on the 4-week average of 57.8.
  4. New company-sponsored Phase 3 trials: 22 registered. Level with the 4-week average of 21.3.
  5. Medicines stepping up a phase: 6 medicines entered a higher trial phase. Tuesday's list has the 12 largest.
  6. Disease with the most new company trials: Diabetes Mellitus, Type 2, 2 new trials.
  7. Medicine approvals: 3 approvals recorded. Down 29% on the 4-week average of 4.3.
    Source: FDA

How this list is made

Each line compares the 7 days to yesterday with the average of the 4 weeks before; a line is left out while its source has no record for the week yet. Raises are SEC Form D sales by operating biotech, pharmaceutical and health care companies (funds and vehicles left out). Trials are registrations on ClinicalTrials.gov; approvals, clearances and warning letters come from FDA records.

Sources: SEC EDGAR, Form D, ClinicalTrials.gov, FDA.

Get the free weekly round-up every MondayEvery Monday: the week's private raises, IPO filings and deals filed with the SEC, each with its filing, and the most covered news about those companies. No account needed.

See the latest edition